This application requests continued support of our drug design efforts aimed both at novel ligands that are dopamine receptor (DAR) isoform-selective agonists, and that can be used as tools to probe the structure and function of this subfamily of GPCRs. Although we are one of the few academic laboratories in the world actively pursuing these lines of research, this project has had a long and successful history in the design and synthesis of dopamine D1/D5 agonists, and their use in understanding DAR function. The design and synthesis efforts supported by this work occur in the context of an independently funded long-term collaboration that provides important pharmacological and computational input. One direction to be pursued is synthesis and characterization of new molecules that will permit the development of a body of data that would lead to the design of agonists selective for the D5, the D1, or both isoforms. These are classes of drugs that do not currently exist, but for which there would be exquisite research and even clinical utility. Full efficacy dopamine D1/D5 agonists are starting to be recognized for their potential as the most effective therapeutic agents for the treatment of mid- and late stage Parkinson's disease, and there is now good evidence that such agonists may also be useful in treating cognitive deficits induced by certain neuroleptics, improving memory, in reversing the negative symptoms of schizophrenia, etc. The approach to be employed is driven by medicinal chemistry and proposes the synthesis of structural modifications that focus on the B-phenyl-B-dopamine pharmacophore that we have identified and used as a template with outstanding success. We have produced three structurally diverse dopamine agonists from this template, and all of them have shown remarkable efficacy vs MPTP-parkinsonism in nonhuman primates. This work provides a foundation for molecular exploitation that will lead to additional important compounds. These will define structure-activity relationships that will help to define the nature of the binding domains necessary to activate the target dopamine receptors. We shall also follow-up on substantial improvements in pharmacokinetic properties we have made without sacrificing desired pharmacodynamic characteristics. The products of this work have a high likelihood of significant impact on basic studies of receptor function, and on the therapy of numerous CNS disorders.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-MDCN-4 (02))
Program Officer
Brady, Linda S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Purdue University
Schools of Pharmacy
West Lafayette
United States
Zip Code
Clark, Alia H; McCorvy, John D; Conley, Jason M et al. (2012) Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine Dýýý receptor-selective full agonist ligand. Bioorg Med Chem 20:6366-74
Chemel, Benjamin R; Bonner, Lisa A; Watts, Val J et al. (2012) Ligand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D(1) receptor catechol agonists. Mol Pharmacol 81:729-38
Cueva, Juan Pablo; Chemel, Benjamin R; Juncosa Jr, Jose I et al. (2012) Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines. Eur J Med Chem 48:97-107
Bonner, Lisa A; Laban, Uros; Chemel, Benjamin R et al. (2011) Mapping the catechol binding site in dopamine D? receptors: synthesis and evaluation of two parallel series of bicyclic dopamine analogues. ChemMedChem 6:1024-40
Cueva, Juan Pablo; Gallardo-Godoy, Alejandra; Juncosa, Jose I et al. (2011) Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7ýý-, 7ýý-, 8ýý-, and 8ýý-methyl substituted dihydrexidine analogues. J Med Chem 54:5508-21
Clark, Alia H; McCorvy, John D; Watts, Val J et al. (2011) Assessment of dopamine Dýýý receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393. Bioorg Med Chem 19:5420-31
Bonner, Lisa A; Chemel, Benjamin R; Watts, Val J et al. (2010) Facile synthesis of octahydrobenzo[h]isoquinolines: novel and highly potent D1 dopamine agonists. Bioorg Med Chem 18:6763-70
Przybyla, Julie A; Cueva, Juan P; Chemel, Benjamin R et al. (2009) Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors. Eur Neuropsychopharmacol 19:138-46
Cueva, Juan Pablo; Giorgioni, Gianfabio; Grubbs, Russell A et al. (2006) trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist. J Med Chem 49:6848-57
Ryman-Rasmussen, Jessica P; Nichols, David E; Mailman, Richard B (2005) Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Mol Pharmacol 68:1039-48

Showing the most recent 10 out of 48 publications